US2022174958A1PendingUtilityA1

Liquid antimicrobial composition

Assignee: GAMA HEALTHCARE LTDPriority: Mar 28, 2014Filed: Jan 20, 2022Published: Jun 9, 2022
Est. expiryMar 28, 2034(~7.7 yrs left)· nominal 20-yr term from priority
A01N 47/44A01N 37/44A01N 43/40A61P 17/00A61Q 19/10A01N 37/46A01N 33/12A01N 25/34A01N 25/30A61K 8/0208A61Q 19/00A61K 8/88A61K 2800/544A61Q 17/005A61P 31/04A61K 2800/51A01N 2300/00A61K 8/416A01N 25/04A61K 8/43
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A liquid antimicrobial composition is provided for use in the disinfection of the skin of a human or an animal, in particular where disinfection of a drug resistant organism is required. The composition comprises a cationic, cell membrane-disrupting biocide and a cationic dendrimer capable of inhibiting an efflux pump mechanism of said cell membrane. The cationic, cell membrane-disrupting biocide is preferably any or a combination of chlorhexidine, a polymeric biguanide, octenidine dihydrochloride and a quaternary ammonium compound. The dendrimer is provided to bind and disrupt the cell membranes of microorganisms in order to inhibit or destroy the cell's efflux pump mechanism thereby preventing microorganism strains resistant to the cationic membrane-disrupting biocide from becoming prevalent, particularly if the biocide comprises chlorhexidine. The dendrimer is preferably a G-0 to G-3 dendrimer comprising any or a combination of quaternary ammonium functionalised poly(propylene imine), polylysine, dendrimers with surface groups based on a sugar and polyamide amine (PAMAM) dendrimers. The composition is preferably in the form of an aqueous or aqueous alcohol solution, dispersion or emulsion that may have been adsorbed by a wipe.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . Cationic dendrimer for inhibiting an efflux pump mechanism of a cell membrane. 
     
     
         2 . Dendrimer according to  claim 1 , wherein the dendrimer is any of a generation 0 to generation 3 dendrimer or a combination of same. 
     
     
         3 . Dendrimer according to  claim 1 , wherein the dendrimer is of generation 1. 
     
     
         4 . Dendrimer according to  claim 1 , wherein dendrimer is any or a combination of quaternary ammonium functionalised poly(propylene imine), polylysine, dendrimers with surface groups based on a sugar and polyamidoamine (PAMAM) dendrimers. 
     
     
         5 . Dendrimer according to  claim 1 , wherein the dendrimer is poly(propylene imine). 
     
     
         6 . Dendrimer according to  claim 1 , wherein the dendrimer is a polyamidoamine (PAMA) dendrimer. 
     
     
         7 . Dendrimer according to  claim 1 , wherein the dendrimer is a polyamidoamine (PAMAM) dendrimer of generation 1. 
     
     
         8 . Antimicrobial composition comprising the dendrimer according to  claim 1 . 
     
     
         9 . Antimicrobial composition according to  claim 8  for use in the disinfection of the skin of human or animal. 
     
     
         10 . Cationic dendrimer according to  claim 1  for use in the disinfection of the skin of human or animal. 
     
     
         11 . Dendrimer according to  claim 1  for use in the prevention or treatment of an infection by microorganisms, in particular drug-resistant organisms. 
     
     
         12 . Antimicrobial composition according to  claim 8  for use in the prevention or treatment of an infection by microorganisms, in particular drug-resistant organisms. 
     
     
         13 . A method for disinfecting the skin of a human or animal comprising:
 applying an antimicrobial composition to the skin of the human or animal, wherein the antimicrobial composition comprises a cationic dendrimer for inhibiting an efflux pump mechanism of a cell membrane.

Join the waitlist — get patent alerts

Track US2022174958A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.